- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Artificial Intelligence and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Insights 68 results
Article · Source: Intellectual Property Strategist
June 1, 2024
Federal Circuit Overrules 'Rosen-Durling' Test for Design Patent Obviousness
Client Alert
May 23, 2024
Federal Circuit Overrules Rosen-Durling Test For Design Patent Obviousness
Client Alert
December 19, 2023
The Administration Takes Aim At Drug Prices Again – This Time Through A Controversial Framework for Exercising March-In Rights
Client Alert
February 13, 2023
U.S. International Trade Commission to Investigate Potential Waiver of International Intellectual Property Rights for COVID-19 Diagnostics and Therapeutics
Article · Source: Los Angeles Lawyer Magazine
December 20, 2022
Barristers Tips; Protecting Developers From Lootbox Litigation
Client Alert
October 14, 2022
Andy Warhol And Prince Go To Washington: Supreme Court Hears Argument On Fair Use
Article · Source: Law360
May 5, 2022
2nd Circ. Ruling Highlights Risks In Trade Secret Licenses
Client Alert
May 3, 2022
Assessing the Value of Intellectual Property Rights in M&A Deals Involving Government Contractors
Client Alert
March 24, 2022
Potential Remedies for Russia’s Suspension of Foreign Investors’ Intellectual Property Rights
Client Alert
December 9, 2021
Agencies Revise Position on Standards-Essential Patents
Article · Source: Law360
February 3, 2021
Challenging Therapeutics IP After Fed. Circ. Drink Can Ruling February 2021
Article · Source: JDSupra
January 7, 2021
The Federal Circuit’s Ball Metal Decision Raises Important Considerations for Pharma and Biologics Patents